慢性乙型肝炎治疗性疫苗研究进展  

Research Progress of Therapeutic Vaccine for Chronic Hepatitis B

作　　者：陆蒙吉[1] 孙航[2] LU Mengji;SUN Hang(Institute for Virology,University Hospital of Essen,University of Duisburg-Essen,Essen 45147,Germany;Institute for Viral Hepatitis,the Second Affiliated Hospital,Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]杜伊斯堡-埃森大学医学院病毒研究所,北莱茵-威斯特法伦州埃森,45147 [2]重庆医科大学附属第二医院病毒性肝炎研究所,重庆400016

出　　处：《药学进展》2022年第10期761-770,共10页Progress in Pharmaceutical Sciences

基　　金：德国自然科学基金(No.RTG1949);国家自然科学基金(No.81871608)。

摘　　要：目前慢性乙型肝炎(CHB)抗病毒治疗的预定目标是“功能性治愈”。用目前可及的治疗药物,只有小部分CHB患者得以实现。针对乙肝病毒(HBV)的特异性免疫反应功能失调被认为是导致HBV持续感染的主要原因,调节宿主免疫系统以加强特定的细胞免疫反应可能有助于清除HBV。治疗性疫苗,包括蛋白质(HBsAg/preS和HBc Ag)、DNA和基于病毒载体的疫苗,能够诱导和加强针对HBV的特异性免疫反应。至今已进行50多项临床试验来评估CHB治疗中的治疗性疫苗,其中一些结果显示出免疫治疗的潜力。综述慢性HBV感染治疗性疫苗有关的基础和临床研究进展,讨论目前临床试验不理想的结果和未来策略。The current intended goal of antiviral therapy for chronic hepatitis B(CHB)is a"functional cure",which can be achieved in a minority of CHB patients with therapeutic agents currently available.Dysfunctional specific immune responses against hepatitis B virus(HBV)are thought to be the main cause of persistent HBV infection,and modulation of the host immune system to enhance specific cellular immune responses may contribute to HBV clearance.Therapeutic vaccines,including protein(HBsAg/preS and HBcAg),DNA and viral vector-based vaccines,are capable of inducing and enhancing HBV-specific immune responses.To date,more than 50 clinical trials have been conducted to evaluate therapeutic vaccines in the treatment of CHB,with some results showing potential for immunotherapy.This review summarizes the progress of basic and clinical research related to therapeutic vaccines for chronic HBV infection and discusses the unsatisfactory results of current clinical trials and future strategies.

关 键 词：乙肝病毒 细胞免疫 免疫疗法 治疗性疫苗 

分 类 号：R512.6[医药卫生—内科学]